Arsenic Trioxide Phebra

Arsenic Trioxide Phebra contains arsenic trioxide 10 mg, sodium hydroxide, hydrochloric acid for pH adjustment, and water for injections to 10 ml.

Arsenic Trioxide Phebra is indicated for induction of remission, and consolidation in adult patients with newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 103/μl) in combination with all-trans-retinoic acid (ATRA) or patients with relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.

  • Strength: 1 mg/ml (10 mg in 10 ml)
  • Package: 10 ml vial
  • Phebra Code: INJ208
  • Pack Size: 10 vials